Group 1 - The core issue involves ST Xiangxue and its actual controller Wang Mouhui facing penalties for violations of information disclosure regulations [1] - ST Xiangxue's 2019 annual report contained false records, and there were significant omissions regarding non-operating fund occupation by related parties from 2016 to 2020 [1] - The Guangdong Securities Regulatory Bureau imposed a fine of 6 million yuan on ST Xiangxue and 10 million yuan on Wang Mouhui, with additional fines for other executives [1] Group 2 - ST Xiangxue reported a total revenue of 818 million yuan in the first half of 2025, a year-on-year decline of 25.40%, and a net loss attributable to shareholders of 234 million yuan [2] - The company's revenue has decreased from over 3 billion yuan in 2020 to more than 1.8 billion yuan in 2024, with net losses for four consecutive years [2] - As of September 5, ST Xiangxue's stock price increased by 10.41% to 11.24 yuan per share, with a market capitalization of 7.433 billion yuan [2]

本报（chinatimes.net.cn）记者于娜 北京报道 上海阳光医药采购网近日连发三则重磅公告，因未按要求调整价格，28个临床常用药品被暂停采购资 格。此次"拉黑"名单涵盖板蓝根颗粒、穿心莲片等家庭常备药，以及心脑康胶囊、复方氨基酸注射液等 刚需品种，太极集团、天津同仁堂等知名药企赫然在列。 上海此次药价治理并非孤立事件，而是全国"四同药品"（同通用名、同剂型、同规格、同厂家）价格协 同治理的一部分，国家医保局通过"省际间价格公平诚信、透明均衡"机制，确保本地挂网价不高于全国 监测价水平，逐步消除省际间的价格差异。此前，内蒙古在今年7月对板蓝根颗粒的调价要求与上海形 成南北呼应，两地整治形成协同效应。 价格调整背后的博弈 上述三份暂停采购公告如同投入湖面的巨石，在医药行业激起层层涟漪。公告显示，因未按要求调整价 格，包括太极集团四川绵阳制药的板蓝根颗粒、天津同仁堂的穿心莲片、山西万辉制药的心脑康胶囊等 25个中成药品种，以及复方氨基酸注射液等3个西药品种被暂停采购资格。 关于暂停部分药品采购资格的通知 发布日期:2025-09-01 【字体:太 中 小】 各医疗机构、各药品生产企业: 根据国家医疗保障局 ...

涉事企业如太极集团、天津同仁堂虽表态"积极配合调价"，但尚未公布具体方案。对此，9月4日，《华 夏时报》记者致电太极集团证券事务部，工作人员表示相关问题需向公司综合管理部门了解，截至发 稿，记者尚未收到回复。 上海此次药价治理并非孤立事件，而是全国"四同药品"（同通用名、同剂型、同规格、同厂家）价格协 同治理的一部分，国家医保局通过"省际间价格公平诚信、透明均衡"机制，确保本地挂网价不高于全国 监测价水平，逐步消除省际间的价格差异。此前，内蒙古在今年7月对板蓝根颗粒的调价要求与上海形 成南北呼应，两地整治形成协同效应。 价格调整背后的博弈 上述三份暂停采购公告如同投入湖面的巨石，在医药行业激起层层涟漪。公告显示，因未按要求调整价 格，包括太极集团四川绵阳制药的板蓝根颗粒、天津同仁堂的穿心莲片、山西万辉制药的心脑康胶囊等 25个中成药品种，以及复方氨基酸注射液等3个西药品种被暂停采购资格。 上海阳光医药采购网近日连发三则重磅公告，因未按要求调整价格，28个临床常用药品被暂停采购资 格。此次"拉黑"名单涵盖板蓝根颗粒、穿心莲片等家庭常备药，以及心脑康胶囊、复方氨基酸注射液等 刚需品种，太极集团、天津同仁堂等知名药 ...

Core Viewpoint - The article discusses the ongoing price governance of traditional Chinese medicine (TCM) products across multiple provinces in China, highlighting the significant price discrepancies and the government's efforts to regulate these prices to alleviate the financial burden on patients and the healthcare system [2][3][5][21]. Group 1: Price Governance Initiatives - Multiple provinces, including Guangxi, Liaoning, Heilongjiang, and Tianjin, have announced price governance measures for TCM products, indicating a nationwide effort to address high prices [2][3]. - The National Healthcare Security Administration (NHSA) has issued a report identifying TCM products with prices significantly higher than the lowest available options, prompting provincial authorities to take action [15][16]. Group 2: Price Discrepancies - There are extreme price differences for the same TCM products across different regions, with some products priced over 100 times higher than the lowest price available [6][9][10][11][12]. - For example, in Ningxia, a single unit of An Gong Niu Huang Wan is priced at 998 yuan, which is 11 times the lowest daily treatment cost for the same product [8]. Group 3: Factors Contributing to Price Variability - Price differences can be attributed to variations in ingredients, dosage forms, quality standards, and insufficient market competition, leading to concentrated pricing power among certain manufacturers [13]. - The complexity of TCM formulations and the lack of standardized quality control further exacerbate pricing issues [24]. Group 4: Impact on Pharmaceutical Companies - The price governance measures affect various pharmaceutical companies, including both small enterprises and established publicly listed firms like Tai Chi Group and Huason Pharmaceutical [21]. - Companies are under pressure to adjust their pricing strategies in response to the new regulations, with some indicating that the impact on their operations will be minimal [22]. Group 5: Patient Benefits and Future Outlook - The governance is expected to reduce the financial burden on patients, particularly for commonly used medications for chronic diseases, promoting fairer pricing and rational drug use [23]. - Experts suggest that while price governance is a step forward, it may not fully resolve the issue of price discrepancies, and additional measures such as collective procurement and improved industry standards are necessary [24].

Group 1 - Kaichun Co., Ltd. adjusted the share repurchase price limit from 26.625 yuan/share to 40 yuan/share, effective from June 10, 2025 [1] - Yipin Pharmaceutical's subsidiary received a drug registration certificate for Dexmedetomidine Hydrochloride Injection, a Class 3 chemical drug used for sedation during anesthesia [1] - Bohui Innovation obtained a medical device registration certificate for HPV Genotyping Test Kit, used for qualitative detection of HPV DNA [1][2] Group 2 - Lingyi Zhi Zao's application for issuing convertible bonds and cash payment to acquire 66.46% of Jiangsu Kedasiteng Automotive Technology Co., Ltd. has been accepted by the Shenzhen Stock Exchange [3] - Kemin Food reported a 23.06% year-on-year increase in pig sales in May, with a total of 48,300 pigs sold [4][5] - Meian Sen decided to terminate the issuance of shares to specific objects due to market conditions and strategic considerations [6][7] Group 3 - Zhengbang Technology reported a 146.6% year-on-year increase in pig sales revenue in May, totaling 731 million yuan [9] - Yuanda Holdings plans to reduce the registered capital of its subsidiary from 73 million to 24.3 million USD to optimize asset structure [10] - East China Pharmaceutical's subsidiary received FDA approval for clinical trials of HDM1010 tablets for type 2 diabetes [12] Group 4 - Liangxin Co., Ltd. received a government subsidy of 14.1 million yuan, accounting for 4.52% of its audited net profit for 2024 [13] - Erkang Pharmaceutical's Vitamin B6 Injection passed the consistency evaluation for generic drugs [14] - New Industry received a patent certificate for an antibody related to anti-PIC detection, enhancing detection efficiency [16][15] Group 5 - Dongxing Medical signed a 6 million yuan technology development contract with Shanghai Jiao Tong University for collagen preparation processes [16] - Suchang Chai A's subsidiary will absorb and merge another subsidiary, adjusting internal equity structure [17] - Yibin Technology received a project designation notice from a domestic new energy vehicle company, with an estimated total sales of 256 million yuan over five years [18] Group 6 - Mingchen Health received a cash dividend of 20 million yuan from its subsidiary [19] - Hendi Pharmaceutical obtained a drug registration certificate for Ibuprofen Suspension, a common medication for children [19] - Huaren Pharmaceutical's subsidiary received a drug registration certificate for Dexmedetomidine Hydrochloride Injection, classified as a Category B drug under national medical insurance [20] Group 7 - Enwei Pharmaceutical obtained a renewed drug production license for six key products [21] - Xiaoming Co., Ltd. reported a 45.59% year-on-year increase in chicken product sales in May, totaling 23.25 million birds [23][24] - Shan Natural Gas successfully issued a 350 million yuan short-term financing bond with a 1.78% interest rate [25] Group 8 - Xidamen announced plans for board members to reduce their holdings by up to 581,000 shares [26] - Shentong Technology's shareholder plans to reduce holdings by up to 3% of the company's shares [27] - Saintno Bio plans to distribute a cash dividend of 0.14 yuan per share and a capital increase of 0.4 shares per share [28] Group 9 - *ST King Kong's subsidiary received a debt transfer notice from its controlling shareholder, totaling 364 million yuan [29] - Foxit Software's executives plan to reduce their holdings by a total of 55,800 shares [30] - Youyou Green Energy plans to apply for a bank credit line of up to 1.5 billion yuan [31] Group 10 - Guoxing Optoelectronics plans to distribute a cash dividend of 0.5 yuan per 10 shares [32] - Guangxun Technology plans to distribute a cash dividend of 2.6 yuan per 10 shares [33] - Hanrui Cobalt plans to distribute a cash dividend of 1.5 yuan per 10 shares [35] Group 11 - Tigermed plans to distribute a cash dividend of 3 yuan per 10 shares [37] - Shenliang Holdings plans to distribute a cash dividend of 1.5 yuan per 10 shares [38] - Yishitong plans to distribute a cash dividend of 1 yuan per 10 shares [39]

当前位置：首页> 政府信息公开（资源库）> 政府信息公开目录> 区市场监督管理局> 重点领域信息公开> 市场监管> 食品药品监管> 监督检查 | 蒙号 | 311392064/2024-77186 | 公开方式 | 主动公开 | | --- | --- | --- | --- | | 公开范围 | 面向社会 | 公开时限 | 长期公开 | | 发布単位 | 区市场监管局 | 发文日期 | 2024-12-16 | 2024年临安区药品抽样结果公示-第二批 今日临安 魅力临安 政务公开 政务服务 政長宣列 量 请输入关键字 日期：2025-05-16 11:02 来源： 浏览量：4 | | | | 店 | 格 | | --- | --- | --- | --- | --- | | 16 SCY2433010072 十滴水 | 230207 | 广东南国药业有限公司 | 杭州临安吴越老百姓大药房有限公司板桥 | 合 | | | | | 店 | 格 | | 17 SCY2433010073 小儿感冒颗粒 | 237056 | 华润三九（枣庄）药业有限公司 | 杭州临安吴越老百姓大药房有限公司板桥 | 合 | | | ...